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Most known disease-associated mutations are
missense mutations involving changes of amino
acids of proteins encoded by their genes. Given the
plethora of genetic studies, sequenced exomes,
and new protein structures determined each year, it
is appropriate to revisit the role that structure plays
in providing insights into the molecular basis of dis-
ease-associated mutations. In that regard, a large-
scale structural analysis of 6,025 disease-associated
mutations as well as 4,536 neutral variations for com-
parisonwas performed.While buried amino acids are
common among the disease-associated mutations,
as reported previously, more are statistically signifi-
cantly enriched at observed or predicted functional
sites. Interesting findings are that ligand-binding
sites adjacent to protein-protein interfaces and resi-
dues involved in enzymatic function are especially
vulnerable to disease-associated mutations. Finally,
a compositional analysis of disease-associated
mutations in comparison with variants identified in
the 1000 Genomes Project provides a structural ra-
tionalization of the most disease-associated residue
types.
INTRODUCTION
Since the sequencing of the first human genome was completed
a decade ago (Collins et al., 2004), tremendous efforts have been
made to advance new sequencing methods that allow rapid,
massively parallel sequencing at low cost (Metzker, 2010). These
next-generation sequencing methods enable large-scale se-
quencing on thousands of individuals, generating a large amount
of data available for comparative genome analysis (Abecasis
et al., 2010, 2012). By identifying variations of DNA sequences,
in particular, Single Nucleotide Polymorphisms (SNPs), we may
begin to decipher the links between phenotypes and genotypes.
Of particular interest are geneticmutations that cause various hu-
man, especially Mendelian, diseases. Statistical analyses of pa-
tients’ and normal people’s sequences often pinpoint mutations
strongly associated with patients. Many such mutations are
collected in databases such as theOnlineDatabase ofMendelian1362 Structure 23, 1362–1369, July 7, 2015 ª2015 Elsevier Ltd All rigInheritance in Man (OMIM) (McKusick, 2007) and the Human
Gene Mutation Database (HGMD) (Stenson et al., 2008).
Since most cases in these databases are SNPs identified
through statistical analysis, it is not clear whether a particular
mutation is actually the cause of the implicated disease. These
mutations are usually referred to as being disease associated.
Most are non-synonymous SNPs (nsSNPs), which occur in the
coding regions of genes and result in changes of amino acid
type, i.e., missense mutations. It is therefore expected that the
change of amino acid impairs the function of the involved pro-
tein. However, for the vast majority of cases, it is not clear how
the mutation affects the function of the protein. In this regard,
studying the impact of mutations may provide a better under-
standing of the mechanisms of the corresponding diseases
and eventually may significantly increase the chance of finding
a better treatment for patients with the disease.
Meanwhile, over a comparable period, the three-dimensional
structures of many proteins have been determined at high reso-
lution (Berman et al., 2000). Often, these proteins are co-crystal-
lized with other biomolecules that are relevant to their functions,
e.g., protein-protein complexes and protein-ligand complexes.
Given these structural data, many questions regarding dis-
ease-causing mutations can be asked and addressed by a thor-
ough inspection of these structures: canwe understand disease-
associated mutations in the context of their locations in the
structure of the protein?Where are disease-linkedmissensemu-
tations located in the proteins? What are the functional and
structural consequences of these mutations? Is there any loca-
tion in the protein where variations are more likely to cause
disease? What is the structural reason why certain types of mu-
tations are more likely to be disease associated? Answers to
these questions not only deepen our understanding of the mo-
lecular mechanisms of diseases but also have practical implica-
tions for the predictions of disease association by automated
computational tools and for personalized medicine.
Over a decade ago,Wang andMoult (2001) performed an early
study of 262 disease-associated mutations from 26 proteins and
found that about 80%of them destabilize proteins and about 5%
involve ligand binding. A subsequent study by Steward et al.
(2003) of 1,292 mutations from 63 proteins showed that about
28% are buried and related to protein stability, while 29% are
involved in intermolecular interactions such as protein-protein
interactions and ligand binding. Similar results were also re-
ported in another study (Sunyaev et al., 2000). However, mainly
due to the paucity of solved protein structures, these studies
were carried out on very few proteins. Since then, many newhts reserved
Table 1. Locations of Disease-Associated Amino Acid Mutations
in Protein Structures
Location Count (Frequency)
Buried 2,211 (0.22)
PPI 726 (0.12)
Ligand binding 714 (0.12)
Metal ion binding 174 (0.029)
DNA/RNA binding 42 (0.007)
Geometric pocket 2,177 (0.36)
EFICAz 420 (0.07)
FINDSITE 738 (0.12)
Other (exposed) 1,451 (0.30)
Total 6,025disease-causing mutations have been found, and the number of
known protein structures has also grown exponentially, espe-
cially for those in complex with functional partners. The previous
studies also lacked a comparison with neutral variations. The
statistical significance of their discoveries, in particular, the value
of structural analysis to the prediction of disease association, is
unclear.
Given this background, it is worthwhile revisiting the questions
raised above. In this study, we performed a large-scale analysis
of 6,025 disease-associated mutations in 642 proteins with
experimental structures, as well as 4,536 neutral mutations in
1,743 proteins for comparison. We took advantage of the fact
that many of these proteins have multiple structures in complex
with other proteins or ligands. Below, we first map these muta-
tions to their locations onto protein structures. We then compare
them with neutral variations and identify regions more likely to
cause disease. We also analyze the likelihood that different
amino acid types are disease associated and provide structural
explanations for some of the most deleterious mutations.
RESULTS
We have collected 6,025 disease-associated missense muta-
tions in 642 human genes and 4,536 neutral mutations in 1,743
human genes from the August, 2013 release of the UniProt
(Universal Protein Resource) database (see Experimental Proce-
dures) (Wu et al., 2006). All these mutations have at least one
experimentally determined protein structure containing the
corresponding mutation. The locations of these mutations are
subsequently analyzed.
Where Are the Disease-Associated Missense Mutations
in Their Protein Structures?
Table 1 shows the statistics of disease-associated mutations.
About 22% are buried in protein cores; 12% are found at pro-
tein-protein interfaces (PPIs); 36% are located in concave
pockets; 12% and 2.9% are found in direct physical contact
with small-molecule ligands and metal ions, respectively; and a
small fraction, 0.7%, are at either DNA-protein or RNA-protein
interfaces. Since the experimental information is most likely
incomplete, we further applied two computational tools, EFICAz
for enzyme function prediction (Kumar and Skolnick, 2012) andStructure 23, 1FINDSITEcomb for ligand-binding site predictions, to our datasets
(Zhou and Skolnick, 2013). About 7%of disease-associated mu-
tations are classified by EFICAz as being functional discrimi-
nating residues (FDRs) for their corresponding enzymatic func-
tions, and an additional 12% of mutations are at FINDSITEcomb
predicted ligand-binding sites that did not have bound ligands
in their PDB structures. It should be noted that these location
classifications are not necessarily mutually exclusive, e.g., about
69% and 45% of observed small-molecule ligand-binding sites
are found in geometric pockets or predicted by FINDSITEcomb,
respectively. Another interesting observation is that about 15%
of disease-associated mutations of observed ligand-binding
sites are also identified at the PPIs. This is investigated in detail
below.
Figure 1 shows a pie chart obtained by assigning a unique pri-
mary location to each mutation, using the following order: DNA/
RNA binding, ion binding, small-molecule ligand binding, PPI,
buried, EFICAz, FINDSITEcomb, pocket, and other exposed.
About 15% of disease-associated mutations are located at
known functional sites, i.e., they involve binding to other mole-
cules than proteins; 10% are at PPIs; and 20% of mutations
are within protein cores and are likely important for maintaining
stability. EFICAz and FINDSITEcomb in addition flagged 3% and
5% of mutations that are potentially important for the functions
of the corresponding protein. After these classifications, 17%
of mutations are found in pockets, which might engage in un-
known interactions with some biomolecules. Overall, this classi-
fication scheme could assign a primary functional or structural
role for 70% of disease-associated mutations. The remaining
30% of mutations involve exposed surface residues and are
located at either a flat surface or small pocket. They are poten-
tially candidate interaction sites for unknown protein-protein in-
teractions or interactions with biomolecules that do not require
large concave pockets.
How Useful Is Structural/Functional Information
for Predicting Disease Association?
In order to answer this question, we compared the frequency of
disease-associated mutations versus neutral mutations at
different locations derived from our structural and functional
analysis mentioned above. As shown in Figure 2A, in all loca-
tions except for unannotated, exposed regions, disease muta-
tions are more likely to appear than neutral mutations. In the
protein interior, the frequency of disease mutations is over
two times that of neutral mutations. This gives an odds ratio
(OR) of 2.66, which is the odds of disease versus neutral among
buried mutations over the odds of disease versus neutral
among all other mutations in our sets. The result is statistically
highly significant, with a p value 4.0 3 1067 (Fisher’s exact
test, two-tailed). Likewise, ligand-binding sites are about 50%
more likely to be observed in the disease set than in the neutral
set, which gives a significant OR of 1.53 (p = 6.8 3 1012). At an
OR of 1.75 (p = 4.4 3 1021), the performance of FINDSITEcomb
in terms of OR is slightly better than that obtained by counting
observed ligand-binding sites in experimental structures. Within
a PPI, or pocket region, disease mutations are slightly, but
significantly, more frequent than neutral mutations, yielding
ORs of 1.23 (p = 1.3 3 103) and 1.09 (p = 0.04), respectively.
The latter is less significant, partly due to the fact that not all362–1369, July 7, 2015 ª2015 Elsevier Ltd All rights reserved 1363
Figure 1. Pie Charts of Disease-Associated
Mutations According to Their Primary
Locations
On the left are the overall distributions; on the right
are the charts of positive hits by FINDSITE and
EFICAz, respectively.residues identified in a predicted, geometric protein pocket are
important for protein function or stability; thus, there are more
noisy signals in this region. Surprisingly, EFICAz predictions
have the highest OR, of about 17 (p = 1.6 3 1078). Many of
these predictions are at highly conserved active sites important
for enzymatic function, although they cover only about 7% of
disease mutations. On the other hand, among unannotated sur-
face residues, neutral mutations have a high percentage at
45%, compared with about 30% of disease mutations. This is1364 Structure 23, 1362–1369, July 7, 2015 ª2015 Elsevier Ltd All rights reservedexpected, as surface residues without a
functional or structural role are less likely
to cause disease.
Since neutral mutations are from a
much more diverse set of proteins than
disease-associated mutations (1,743
versus 642 proteins), there is the concern
that the dataset might be biased. In order
to eliminate such a concern, we further
performed the same analysis on the sub-
set of mutations that appear in the same
set of proteins. Figure 2B shows results
that qualitatively are in agreement with
the analysis on the full set shown above.
Mutations Adjacent to PPIs Are
More Likely Associated with
Disease ThanMutations within PPIs
Overall, about 58%of disease-associated
mutations are found in at least one pro-
tein-protein complex structure versus
50% of neutral mutations that are found
in a protein-protein complex. We further
analyzed the distribution of mutations inprotein-protein complexes according to their distance from
observed PPIs (Figure 3A). As shown above, about 12.0% of
all diseasemutations and 10.1%of neutral mutations in our data-
sets are located at the PPIs, i.e., 0 A˚ from the interface. This gives
a small, but statistically significant, difference of 1.9%, corre-
sponding to an increase of about 20% in OR to 1.23 for the
disease-associated mutations. The remaining difference in cu-
mulative fraction comes mainly from the mutations close to but
not at the PPIs. Within 3 A˚ from PPIs, the cumulative differenceFigure 2. Disease-Associated Mutations
Versus Neutral Ones Assigned by Their
Location in the Structure of the Protein
Each bar represents the fraction of mutations in
either disease-associated or neutral datasets. The
numbers above pairs of bars are the ORs. Aster-
isks denote statistical significance according to
one-tailed Fisher’s exact test (*0.01 < P < 0.05;
**0.001 < P < 0.01; ***P < 0.001; no asterisk, P >
0.05).
(A) All mutations.
(B) Subset of mutations from the same set of pro-
teins that contain both disease-associated and
neutral mutations.
LBS, ligand-binding sites.
Figure 3. Distribution of Mutations in the Neighborhood of PPIs
(A) Cumulative fractions of disease-associated mutations versus neutral ones according to their distance from known PPIs.
(B) Subsets of mutations that are also observed at small-molecule ligand-binding sites (LBS).
(C) Distributions of ORs according to distance from PPIs. A bin width of 2 A˚ is employed. Asterisks represent statistical significance as in Figure 2.rapidly increases to 6.8%; this percentage further increases to
8.3% within 6 A˚ from PPIs. Thus, it appears that disease muta-
tions are more likely to occur at and/or adjacent to PPIs than
neutral mutations. Moreover, the biggest difference is attributed
to regions immediately neighboring PPIs, i.e., at a distance from
0 A˚ to 6 A˚, rather than at the PPIs themselves. This difference
leads to a significant increase of OR values to as high as 1.75
at 3 A˚ from PPIs (Figure 3C).
Since disease-causing mutations are more likely to be buried
thanneutralmutations, as shown inFigure 2, onenatural explana-
tion is that buriedmutations close to PPIs are more likely disease
associated than neutral. The difference in cumulative fraction of
buried mutations around PPIs between the disease and neutral
sets is about 0.1% at 0 A˚, 3.5% within 3 A˚, and 5.1% within 6 A˚
from PPIs. Therefore, mutations of buried residues do make a
major contribution to the observed phenomenon. However, this
explains only about 61% of the observed difference.
A second main reason for this phenomenon is that adjacent to
PPIs, there are functionally relevant pockets involving ligand
recognition. It has been shown that protein-protein association
naturally creates geometric pockets (Gao and Skolnick, 2012).
Some of these pockets could be selected by evolution for ligand
binding. As a result, functionally relevant ligand-binding pockets
are enriched around PPIs. Mutations at these pockets likely lead
to harmful effects. Indeed, if we focus on the subset of mutations
that are also ligand binding within protein-protein complexes, we
find that disease-associated mutations are much more likely to
be found in the neighborhood of PPIs versus neutral mutations.
As shown in Figure 3B, the difference in the cumulative fraction
of mutations is 0.9% at 0 A˚ from PPIs, 2.0% within 3 A˚ from
PPIs, and 2.6% within 6 A˚, which could explain about 31% of
the corresponding 8.3% difference in overall cumulative fraction
difference mentioned above. This also contributes to an overall
bump in the OR shown in Figure 3C. Notice that the risk of
being disease associated is about 30% higher in terms of OR
when a mutation is observed in a ligand-binding site within 3 A˚
from a PPI.
Figure 4 shows two examples of disease-associated muta-
tions located at/near PPIs. Medium-chain acyl-coenzyme AStructure 23, 1(CoA) dehydrogenase (ACADM) is one of four enzymes involved
in fatty acid catabolism (Lee et al., 1996). The enzyme is respon-
sible for the a,b-dehydrogenation of fatty acyl-CoA derivatives.
The structure of this protein is a dimer of dimers. Figure 4A
shows the structure of the basic dimer unit, in which the co-fac-
tor FAD (flavin-adenine dinucleotide) is sitting at the dimeric
interface, whereas the fatty substrate is located close by. There
are five known mutations located in the binding sites of these
substrates within 5 A˚. They are linked to ACADMD (ACADMme-
dium-chain deficiency), a disease that can cause sudden death
of infants (OMIM: 201450).
One important benefit of an interfacial pocket formed adja-
cent to PPIs is that it could function as a molecular switch
controlled by the association/dissociation of the protein com-
plex. This is illustrated in an example involving two proteins,
retinitis pigmentosa 2 (RP2) and the small G protein Arf-like 3
(Arl3), which form a complex providing a guanosine triphos-
phate binding pocket at the PPI (Figure 4B) (Veltel et al.,
2008). It is thought that this is a molecular switch for regulating
the ciliary process in photoreceptor cells. Mutations in RP2 that
disrupt ligand binding at the PPI, such as the arginine finger
R118, may cause X chromosome-linked eye disease (OMIM:
312600).
Post-Translational Modifications and Disease
Association
Post-translational modifications play essential roles in many bio-
logical processes. We examined how many disease-associated
mutations are located at such a site compared with neutral mu-
tations. From the UniProt knowledge base, we searched for
experimentally validated modification sites. We found only
27 cases in the disease mutation set and 11 cases in the neutral
set, which gives a p value of 0.1 (Fisher’s exact test, two-tailed).
The most common modifications are glycosylation: nine in the
disease mutations and four in the neutral mutations. If we drop
the requirement of having solved structures, we are able to
match 77 of 23,846 disease mutations and 68 of 37,687 neutral
mutations, which leads to a significant p value of 5.9 3 104.
As one would expect, mutations at post-translational362–1369, July 7, 2015 ª2015 Elsevier Ltd All rights reserved 1365
Figure 4. Examples of Disease-Associated Mutations Observed in
the Neighborhood of PPIs
(A) Dimeric ACADM.
(B) Retinitis pigmentosa 2 and Arl3. In each snapshot, protein structures are
shown in light blue and purple cartoon representations, small molecules are
shown in orange and yellow van der Waals (VdW) representations, and refer-
ence amino acids at themutation sites are also shown in VdW representations,
where carbon, oxygen, and nitrogen atoms are colored in cyan, red, and blue,
respectively.modification sites are significantly more likely to be associated
with disease. However, the cases that can be explained by
such mutations are very small, to the best of our knowledge.
Amino Acid Changes and Disease Association
Finally, we ask the question whether there are certain types of
amino acid changes that are more likely to be disease associ-
ated. Figure 5A shows the frequency of amino acid types from
the original reference amino acid at the mutation sites. Arginine
is the most common mutation in both disease and neutral sets,
due to the fact that four of the six arginine codons contain the
CpG dinucleotide, which is relatively vulnerable to mutations
(Cooper and Youssoufian, 1988). However, because the fre-
quencies of arginine mutations in these two sets are very close,
14.8% versus 14.3%, it is not a good indicator for predicting dis-
ease association. In terms of OR, mutation from Cys is highest at
4.86, followed by Trp at 3.58, and glycine at 2.04. On the other
hand, mutations involving certain hydrophobic residues, such
as valine and isoleucine, are significantly underrepresented in
disease mutations. One explanation is that valine and isoleucine
have similar physicochemical properties and are very close in the
codon space, with only a single nucleotide difference (GUA,
GUC, GUU of valine and AUA, AUC, AUU of isoleucine).
Figure 5B shows the frequencies of amino acids to different
mutated residues. Statistical analysis suggests that mutation
to Pro is most likely damaging, with an OR of 3.46, followed by
CYS at 1.87. It is interesting to note that the frequencies of dis-
ease-causing mutations show a much lower correlation to fre-
quencies of neutral mutations when one compares mutated-to
amino acids versus mutation-from amino acids. The corre-
sponding Pearson correlation coefficients are 0.35 versus 0.73.
This suggests that the mutation-from frequencies are largely
determined by similar reasons, for example, distribution of co-
dons and distances in the codon space (i.e., those with one
nucleotide difference are of high possibilities), whereas muta-
tion-to frequencies are largely determined by very different rea-
sons between the disease and neutral sets.
The 1000 Genomes Project has revealed a large set of variants
in about 1,000 healthy individuals (Abecasis et al., 2012). One
could argue that these variants are a good neutral background
for the purpose of our analysis. We repeated the same composi-1366 Structure 23, 1362–1369, July 7, 2015 ª2015 Elsevier Ltd All rigtion analysis using the data from the 1000 Genomes Project. As
shown in Figures 5C and 5D, we obtained very similar results to
those using the UniProt neutral set. Mutations from and to CYS
give an OR of 2.79 and 1.33, respectively; mutations from Trp
have anOR of 3.58; and theOR ofmutations to Pro is 3.21. These
are also mutations that are most likely associated with diseases
than neutral mutations.
We then sought structural explanation for the top three most
deleterious types of mutations involving Cys, Pro, and Trp amino
acids. First, we ask why mutations from and to a Cys residue are
harmful. Since it is known that Cys often form disulfide bonds, it
is hypothesized that a Cys mutation either disrupts useful disul-
fide bonds in the case of mutation from or introduces an
unwanted disulfide bond in case of mutation to. To test this hy-
pothesis, we examined if there are Cys disulfide bonds in the
structure of the corresponding protein. In the mutation-from
set, about 2/3 of Cys mutations are likely to form a disulfide
bond with another Cys residue nearby within 4.5 A˚, whereas
only about 1/3 of Cys mutations in the neutral set have another
Cys nearby. This gives a highly significant p value of 3.2 3
106. Therefore, disease-associated Cys mutations are more
likely to disrupt an original disulfide bond important for protein
stability or function. On the other hand, in the mutation-to data-
sets, we found that after the mutation to Cys, there are 45 cases
in which there is another Cys nearby in the disease set, versus
only seven cases in the neutral set (p = 0.007). In these cases,
the Cys mutation may introduce an unwanted disulfide bond
that could lead to protein malfunction.
Second, why is a mutation to Pro likely to be harmful? Pro is a
unique amino acid that does not have an hydrogen for backbone
hydrogen bond formation. In addition, it has a more restricted
dihedral angle space than a typical amino acid. This restriction
often creates a kink in helical structures at the position of a
Pro. As a result, mutations to Pro often disrupt helical structures.
We performed an analysis of the secondary structure where a
mutation to Pro occurs, with the result shown in Table 2. The
most common Pro mutation in the disease set lies within a 310
helix, about 36%, in contrast to 23% cases in the neutral set
(p = 0.006). The second common secondary structural element
where a Pro mutation occurs is a turn: 26% in disease versus
18% in neutral (p = 0.1) sites, where a Pro mutation might disrupt
hydrogen bonding. By contrast, in the coil region, where there is
no ordered secondary structure, a Pro mutation is much less
likely present at 20%, in comparison with 32% in the neutral
set (p = 0.009). The result supports the conclusion that the
disruptive presence of a Pro mutation in the secondary structure
is often disease associated.
Lastly, we investigatedmutation from Trp that is often linked to
disease. Trp is the largest amino acid that plays an important role
in protein folding and stability. On average, a Trp residue makes
8.5 side-chain contacts versus 6.0 side-chain contacts of other
types of amino acids. Further calculation estimates that a Trp
mutation in the disease set leads to a mean increase of the
free energy of protein folding DDG of 3.4 kcal/mol (126 cases,
SD = 1.61 kcal/mol), versus 2.9 kcal/mol (27 cases, SD =
1.36 kcal/mol) of Trp mutations in the neutral set (p = 0.076,
t test, two-tailed). This analysis suggests that mutations from
Trp likely destabilize the structure of the protein and result in
less fitness. In the vast majority of cases analyzed, thishts reserved
Figure 5. Composition Analysis of Disease-
Associated Mutations Versus Neutral Muta-
tions from the UniProt database and the
1000 Genomes Database
Amino acids are labeled by their one-letter names.
The color of each type of amino acid represents
ORs of disease mutations versus neutral ones. The
same color scale of OR shown as the insert in (A) is
adopted throughout all other panels. Statistical
significance of association is indicated by asterisks
in the same way as in Figure 2. CC, Pearson cor-
relation coefficient. The dashed line represents an
OR of 1. (A and B), from the UniProt database;
(C and D), from the 1000 Genomes Databasedestabilization likely has a significant impact on the function of
protein, thus leading to various disease conditions.
DISCUSSION
Since the vast majority of disease-associated mutations are
assigned based on statistical analysis, it is not clear whether
a mutation is actually the cause of the implicated disease.
To provide a better understanding of mutations from a struc-
tural prospective, we performed a large-scale analysis of
6,025 disease-associated mutations in 642 proteins. We found
that about 20% of mutations are buried in protein cores and
that these mutations may destabilize protein structures,
whereas about 11% of mutations are involved in ligand bind-
ing, and another 10% are involved in protein-protein interac-
tions. About 17% are in pockets, 3% involve ion binding,
and 1% DNA/RNA binding. These numbers are consistent
with previous studies conducted on smaller datasets (Steward
et al., 2003; Sunyaev et al., 2000). Using computational
approaches, we further predicted that about another 8% of
mutations are likely ligand-binding or essential for enzyme
function. We found a structural/functional annotation for about
70% of mutations. As more experimental structures are deter-
mined for functional complexes of proteins, e.g., in complex
with other ligand or proteins for their function, we expect to
see more mutations explained by the functional roles of the
mutated residues.
In order to demonstrate the usefulness of the structural/
functional data, one needs to compare disease-associated
mutations with neutral mutations. This has been largelyStructure 23, 1362–1369, July 7, 2015ignored or not thoroughly pursued in pre-
vious studies. Here, we show a statisti-
cally significant difference between dis-
ease-associated and neutral mutations.
As pointed out previously (Ng and Henik-
off, 2006), one of the most effective de-
scriptors is the degree of surface expo-
sure of the protein residue at the
mutation site. Buried residues in the dis-
ease set have the second highest OR, at
2.66, compared with neutral ones,
whereas exposed residues not involving
any interactions or pocket-like featureare more likely to be neutral at an OR of 0.50. Functional sites,
such as ligand-binding sites and PPI residues, all have signif-
icant ORs at 1.53 and 1.23. However, they are not as effective
as one naively expects. One reason might be due to purifica-
tion selections, which removed many deleterious, fatal muta-
tions at these functional sites. It is also worth mentioning
that computational predictions achieved good performance.
Predictions by FINDSITEcomb and EFICAz yield OR values at
1.75 and 16.9, respectively, which is comparable with or better
than results obtained by counting known ligand-binding sites
from experimental structures. Most interestingly, it is the pre-
dicted loss of enzymatic function that is most strongly disease
associated. These are encouraging results, which demonstrate
the potential of computational, knowledge-based methods.
One novel observation is that mutations adjacent to PPIs are
more likely associated with disease than mutations at the PPIs
themselves. At 1.75, the OR is highest about 3 A˚ from PPIs,
which is about 40% higher than the OR at PPIs. There are two
contributing factors. One is that the mutations at buried sites
within each monomer but close to the PPIs are more likely to
be disease causing, presumably by destabilizing the protein
complex. The second is due to the presence of interfacial
pockets, which are ligand-binding pockets at or adjacent to
PPIs (Gao and Skolnick, 2012). Mutations within interfacial
pockets could disrupt functionally important ligand-protein inter-
actions. This is supported by subsequent analysis, which shows
that mutations within interfacial pockets have more than double
the OR of mutations at PPIs.
Although amino acid type change is one main factor for as-
sessing pathogenicity of human mutations in many automaticª2015 Elsevier Ltd All rights reserved 1367
Table 2. Analysis of Secondary Structure Location of Mutations
to Proline
Type Disease Neutral Pa
310 helix 195 (0.36) 29 (0.23) 0.003
a helix 21 (0.039) 7 (0.056) 
Turn 139 (0.26) 23 (0.18) 0.049
b sheet 38 (0.071) 11 (0.088) 
Bend 35 (0.065) 15 (0.12) 
Coil 110 (0.20) 40 (0.32) 0.005
Total 538 125
aInsignificant P value is indicated by .
Table 3. Contingency Table for the Statistical Test
Disease Neutral Odds
Positive dpos npos dpos/npos
Negative dneg nneg dneg/nneg
Total 6,025 4,325 annotation tools (Adzhubei et al., 2010; Kumar et al., 2009), in-
depth analysis of why it works is somewhat lacking, although
there have been studies about the frequencies of disease-
associated mutations (de Beer et al., 2013; Vitkup et al.,
2003). Obviously, if the mutation involves very different amino
acid types, e.g., from hydrophobic to charged residues, it is
more likely to cause an issue than mutations among hydropho-
bic residues. Ideally, one would like to study all 380 pairs of
non-synonymous mutations. However, the number of known
disease-causing mutations is currently too limited for such a
study. We opt instead to focus on each type of amino acid,
grouped by mutations from and mutation to a given amino
acid type. We found that certain types of mutations, such as
mutations involving Cys, Trp, or Pro, are more likely to be dis-
ease associated. Through structural analysis, Cys mutations
often involve breaking disulfide bridges or forming unwanted
disulfide bonds; Trp mutations usually significantly destabilize
structures, and mutations to Pro tend to disrupt helical struc-
tures. These analyses provide some examples of how structural
analysis could provide further insights into the mechanisms of
disease.
EXPERIMENTAL PROCEDURES
Dataset
From the August, 2013 release of the UniProt knowledge base (Wu et al.,
2006), we collected 23,846 disease-associated variants and 37,782 polymor-
phisms in human; we assume that the latter are neutral mutations. The classi-
fication was manually assigned according to the literature and a previously
curated database such as OMIM (McKusick, 2007). These variants are all
missense mutations with changes of amino acid type. Unclassified variants
were ignored. From this collection, we further selected those with at least
one experimentally determined structure deposited in the PDB (Berman
et al., 2000). We verified that the protein structure contains the same amino
acid at the position indicated in the UniProt mutation data. To avoid possible
bias, if the gene contains more than 50 variants, we randomly selected no
more than 50 variants in each gene. If multiple variants are found correspond-
ing to the same residue position in a gene, we also randomly selected only one
variant. This procedure yielded 6,025 disease-associated mutations in 642
proteins and 4,536 neutral mutations in 1,743 proteins. These two sets are
the main dataset used in our study. They share 355 common proteins, with
4,209 disease mutations and 1,113 neutral mutations.
Data of the 1000 Genomes Project variants are from de Beer et al. (2013). It
should be noted that the counts of mutations fromOMIM aremislabeled in that
study. The counts of mutations from were mistaken as mutation to, and vice
versa. The mistake in de Beer et al. (2013) gives incorrect amino acid mutation
frequencies, which are inconsistent with a previous study (Vitkup et al., 2003),
whereas our results are in agreement with Vitkup et al. (2003).1368 Structure 23, 1362–1369, July 7, 2015 ª2015 Elsevier Ltd All rigStructural and Functional Analysis
Using the experimental structures, we mapped the location of each mutation.
For each PDB record, we analyzed the structure given by the basic asymmetric
unit, as well as author assigned biounit if it contains protein-protein com-
plexes. The HET code in each PDB header was used to determine the types
of ligand, i.e., metal ion, small-molecule ligand, or DNA/RNA. Note that this
analysis does not guarantee that a ligand has biologically relevant interaction
with its co-crystallized protein. Nevertheless, in many cases, biologically rele-
vant molecules recognize the same binding sites on proteins as other non-bio-
logical molecules. Atomic contacts between protein and ligand were
determined by the program LPC (Sobolev et al., 1999). If the original amino
acid at the mutation site contains at least one heavy atom making physical
contact with a ligand, it is assigned as ligand binding. Similarly, PPI residues
are defined by a heavy-atom distance of 4.5 A˚. The distance between a variant
residue and PPI is defined as the shortest heavy-atom distance between the
residue and any PPI residue. If a protein has multiple complex structures,
we chose the minimal distance among all these complexes. Solvent acces-
sible surface area (SASA) was calculated for each original residue of the muta-
tions using the program NACCESS (Hubbard and Thornton, 1993). If a residue
has less than a 1% relative SASA percentage, it is defined as a buried residue.
Otherwise, the residue is an exposed surface residue. Again, if the residue is
observed in multiple structures, we employed the lowest relative SASA value.
We also ran FINDSITEcomb (Zhou and Skolnick, 2013) to annotate computa-
tionally ligand-binding sites and EFICAz (Kumar and Skolnick, 2012) to predict
FDRs for predicted enzymes. Calculations of the free energy differences,DDG,
of Trp mutations were conducted using the program DMutant, which is based
on statistical potentials (Zhou and Zhou, 2002) and ranked among the top per-
formers in an independent assessment (Khan and Vihinen, 2010). Secondary
structure analysis was carried out using DSSP (Kabsch and Sander, 1983).
Statistical Analysis
With a few noted exceptions, a Fisher’s exact test was conducted on the con-
tingency table given in Table 3. A positive case is a variant containing a certain
feature, such as ligand binding, or a mutation from a Cys residue. A negative
case is a variant without such a feature. Outcomes are either disease associ-
ated or neutral. The counts of positive/negative cases with disease are de-
noted as dpos/dneg, respectively, and similarly, npos/nneg, for positive/negative
cases for neutral ones. Odds are calculated for positive and negative cases
separately, and their ratio yields the OR.
Availability
The datasets are available as Supplemental Information and also online at
http://cssb.biology.gatech.edu/nssnp.
SUPPLEMENTAL INFORMATION
Supplemental Information includes a Supplemental Spreadsheet and can be
found with this article online at http://dx.doi.org/10.1016/j.str.2015.03.028.
ACKNOWLEDGMENTS
This work is supported by grant no. GM-37408 of the Division of General
Medical Sciences of the NIH.
Received: January 26, 2015
Revised: March 3, 2015
Accepted: March 6, 2015
Published: May 28, 2015hts reserved
REFERENCES
Abecasis, G.R., Altshuler, D., Auton, A., Brooks, L.D., Durbin, R.M., Gibbs,
R.A., Hurles, M.E., and McVean, G.A. (2010). A map of human genome varia-
tion from population-scale sequencing. Nature 467, 1061–1073.
Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M.,
Handsaker, R.E., Kang, H.M., Marth, G.T., and McVean, G.A. (2012). An inte-
grated map of genetic variation from 1,092 human genomes. Nature 491,
56–65.
Adzhubei, I., Schmidt, S., Peshkin, L., Ramensky, V., Gerasimova, A., Bork, P.,
Kondrashov, A., and Sunyaev, S. (2010). A method and server for predicting
damaging missense mutations. Nat. Methods 7, 248–249.
Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H.,
Shindyalov, I.N., and Bourne, P.E. (2000). The Protein Data Bank. Nucleic
Acids Res. 28, 235–242.
Collins, F.S., Lander, E.S., Rogers, J., and Waterston, R.H.; International
Human Genome Sequencing Consortium (2004). Finishing the euchromatic
sequence of the human genome. Nature 431, 931–945.
Cooper, D.N., and Youssoufian, H. (1988). The CpG dinucleotide and human
genetic disease. Hum. Genet. 78, 151–155.
de Beer, T.A., Laskowski, R.A., Parks, S.L., Sipos, B., Goldman, N., and
Thornton, J.M. (2013). Amino acid changes in disease-associated variants
differ radically from variants observed in the 1000 genomes project dataset.
PLoS Comput. Biol. 9, e1003382.
Gao, M., and Skolnick, J. (2012). The distribution of ligand-binding pockets
around protein-protein interfaces suggests a general mechanism for pocket
formation. Proc. Natl. Acad. Sci. USA 109, 3784–3789.
Hubbard, S.J., and Thornton, J.M. (1993). NACCESS, Computer Program,
Department of Biochemistry and Molecular Biology (University College
London).
Kabsch, W., and Sander, C. (1983). Dictionary of protein secondary structure–
pattern recognition of hydrogen-bonded and geometrical features.
Biopolymers 22, 2577–2637.
Khan, S., and Vihinen, M. (2010). Performance of protein stability predictors.
Hum. Mutat. 31, 675–684.
Kumar, N., and Skolnick, J. (2012). EFICAz2.5: application of a high-precision
enzyme function predictor to 396 proteomes. Bioinformatics 28, 2687–2688.
Kumar, P., Henikoff, S., and Ng, P. (2009). Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat. Protoc.
4, 1073–1081.Structure 23, 1Lee, H.J., Wang, M., Paschke, R., Nandy, A., Ghisla, S., and Kim, J.J. (1996).
Crystal structures of the wild type and the Glu376Gly/Thr255Glu mutant of
human medium-chain acyl-CoA dehydrogenase: influence of the location of
the catalytic base on substrate specificity. Biochemistry 35, 12412–12420.
McKusick, V.A. (2007). Mendelian Inheritance in Man and its online version,
OMIM. Am. J. Hum. Genet. 80, 588–604.
Metzker, M.L. (2010). Sequencing technologies–the next generation. Nat. Rev.
Genet. 11, 31–46.
Ng, P.C., and Henikoff, S. (2006). Predicting the effects of amino acid substi-
tutions on protein function. Annu. Rev. Genomics Hum. Genet. 7, 61–80.
Sobolev, V., Sorokine, A., Prilusky, J., Abola, E.E., and Edelman, M. (1999).
Automated analysis of interatomic contacts in proteins. Bioinformatics 15,
327–332.
Stenson, P.D., Ball, E., Howells, K., Phillips, A., Mort, M., and Cooper, D.N.
(2008). Human Gene Mutation Database: towards a comprehensive central
mutation database. J. Med. Genet. 45, 124–126.
Steward, R.E., MacArthur, M.W., Laskowski, R.A., and Thornton, J.M. (2003).
Molecular basis of inherited diseases: a structural perspective. Trends Genet.
19, 505–513.
Sunyaev, S., Ramensky, V., and Bork, P. (2000). Towards a structural basis of
human non-synonymous single nucleotide polymorphisms. Trends Genet. 16,
198–200.
Veltel, S., Gasper, R., Eisenacher, E., and Wittinghofer, A. (2008). The retinitis
pigmentosa 2 gene product is a GTPase-activating protein for Arf-like 3. Nat.
Struct. Mol. Biol. 15, 373–380.
Vitkup, D., Sander, C., and Church, G.M. (2003). The amino-acid mutational
spectrum of human genetic disease. Genome Biol. 4, R72.
Wang, Z., and Moult, J. (2001). SNPs, protein structure, and disease. Hum.
Mutat. 17, 263–270.
Wu, C.H., Apweiler, R., Bairoch, A., Natale, D.A., Barker, W.C., Boeckmann,
B., Ferro, S., Gasteiger, E., Huang, H.Z., Lopez, R., et al. (2006). The
Universal Protein Resource (UniProt): an expanding universe of protein infor-
mation. Nucleic Acids Res. 34, D187–D191.
Zhou, H.Y., and Zhou, Y.Q. (2002). Distance-scaled, finite ideal-gas reference
state improves structure-derived potentials of mean force for structure selec-
tion and stability prediction. Protein Sci. 11, 2714–2726.
Zhou, H., and Skolnick, J. (2013). FINDSITEcomb: a threading/structure-based,
proteomic-scale virtual ligand screening approach. J. Chem. Inf. Model. 53,
230–240.362–1369, July 7, 2015 ª2015 Elsevier Ltd All rights reserved 1369
